British Pharmacological Society Strategy 2026-2030

Resetting Pharmacology's Course

The British Pharmacological Society (BPS), a key learned society representing academics, researchers, clinicians, and industry professionals in pharmacology, is developing a new strategic plan for 2026-2030. This follows the conclusion of its prior multi-year strategy, prompting a review of progress and adaptation to external shifts.

The timing is driven by broader changes in the UK research environment. The UK has slipped in global rankings for pharmaceutical R&D investment, clinical trial activity, and foreign direct investment in life sciences. Post-Brexit adjustments and pandemic disruptions contributed to delays in regulatory processing, though recent MHRA reforms have reduced average clinical trial approval times from 91 days to 41 days by mid-2025.

Government initiatives under the Life Sciences Sector Plan target faster commercial trials, with a goal of under 150 days setup time by March 2026, alongside AI integration and streamlined regulations. New clinical trials legislation takes effect in April 2026, embedding risk-based reviews, combined regulatory-ethics assessments, and mandatory public registration and results publication.

These changes carry high stakes. The global life sciences market is projected to exceed $2 trillion by 2028, and delays or lost competitiveness could mean fewer UK-led innovations, reduced early patient access to therapies, and diminished economic contributions from pharma, which supports jobs and growth. Inaction risks further erosion of the UK's position relative to the US, EU, and emerging hubs.

Non-obvious tensions include balancing speed with safety in regulatory acceleration, potential over-reliance on AI without sufficient validation, and the squeeze on learned societies like the BPS amid flat or constrained public funding. While aligned with national industrial strategy and health missions, these efforts must navigate stakeholder differences—academia seeking basic research support, industry demanding quicker returns, and regulators ensuring evidence standards.